Physician profile
William Broughton
NPI 1609827104
$7,074.12
in general payments reported to CMS, 2019-2025
45 companies · $1,970 in 2025
The $1,970 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $433 · 2021: $512 · 2022: $757 · 2023: $1,155 · 2024: $1,455 · 2025: $1,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,520 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,520.34 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,157.72 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $1,012.59 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Regeneron Healthcare Solutions, INC. | $756.16 | 2020-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $550.73 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $408.39 | 2022-2025 | Zerbaxa, Winrevair, Dificid |
| Astrazeneca Pharmaceuticals Lp | $399.94 | 2022-2025 | Tezspire, Fasenra |
| Janssen Pharmaceuticals, INC | $392.78 | 2019-2022 | |
| Genzyme Corporation | $366.46 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $276.08 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $210.92 | 2019-2024 | |
| Philips North America LLC | $164.77 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Mallinckrodt Hospital Products INC. | $154.99 | 2020-2025 | Acthar |
| Astellas Pharma US INC | $107.06 | 2019-2022 | |
| Abbvie INC. | $95.76 | 2023-2025 | Teflaro |
| Mallinckrodt Enterprises LLC | $91.67 | 2019 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $79.25 | 2019-2023 | Ultomiris |
| Mylan Specialty L.P. | $61.64 | 2024 | Yupelri |
| Corcept Therapeutics | $53.18 | 2020-2021 | |
| Theratechnologies INC. | $51.61 | 2025 | Egrifta, Trogarzo |
| Viatris Specialty LLC | $50.88 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $49.28 | 2023-2024 | Purified Cortrophin Gel |
| Mannkind Corporation | $44.84 | 2019 | |
| Sunovion Pharmaceuticals INC. | $37.95 | 2019 | |
| Shionogi INC | $36.62 | 2022-2023 | Fetroja |
| Inogen, INC. | $36.07 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Circassia INC. | $32.36 | 2019 | |
| Lilly USA, LLC | $29.57 | 2019-2022 | |
| Sandoz INC. | $28.36 | 2019-2021 | |
| Inspire Medical Systems, INC. | $28.22 | 2023 | Inspire |
| Amgen INC. | $25.64 | 2024 | Tavneos |
| Calliditas Therapeutics US INC. | $23.25 | 2024 | |
| Grifols USA, LLC | $23.21 | 2020 | |
| Liquidia Technologies, INC. | $22.95 | 2025 | Yutrepia |
| Takeda Pharmaceuticals U.S.A., INC. | $21.79 | 2025 | Cuvitru |
| Invivyd INC | $21.14 | 2025 | Pemgarda |
| Axsome Therapeutics, INC. | $20.55 | 2025 | Auvelity |
| Genentech USA, INC. | $20.46 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.15 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $18.24 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $18.08 | 2022 | |
| Portola Pharmaceuticals, LLC | $16.68 | 2020 | |
| Shire North American Group INC | $16.48 | 2019 | |
| Novo Nordisk INC | $15.61 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.12 | 2021 | |
| Covidien Lp | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Broughton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.